[eGongsi Notice] KOSDAQ - October 29

< After Market Close Major Disclosures >

◆Brand X Corporation = Preliminary consolidated Q3 results: sales 43.1 billion KRW, operating profit 5.5 billion KRW

◆Bioneer = Preliminary consolidated Q3 results: sales 64.0 billion KRW, operating profit 0.1 billion KRW

◆Elcomtec = Preliminary consolidated Q3 results: sales 12.3 billion KRW, operating profit 1.1 billion KRW

◆Piolink = Change of largest shareholder from NHN and 3 others to Igloo Security and 3 others

◆KG Inicis = Preliminary consolidated Q3 results: sales 250.7 billion KRW, operating profit 26.6 billion KRW

◆Jin System = Obtained manufacturing certification for in vitro diagnostic medical devices from Korea Medical Device Safety Information Center under the Ministry of Food and Drug Safety

◆Chunlab = Change of largest shareholder from Chun Jong-sik and 10 others to CJ CheilJedang

◆Bioplus = Decided to acquire 5.53% stake in NovelGen for 30 billion KRW through third-party allotment capital increase

◆Medicox = Change of largest shareholder from Mecox Biomed to L2 1st Association

◆KG ETS = Decided to dispose of 1,965,408 treasury common shares for 10 billion KRW due to exercise of private bond call option

◆CNT85 = Signed a 500 million KRW contract for Songsan warehouse renovation project with Entegris Korea

◆Abaco = Preliminary Q3 results: sales 42.5 billion KRW, operating profit 1.9 billion KRW

◆Chris F&C = Decided to dispose of 451,976 treasury common shares for 20 billion KRW to issue exchangeable bonds targeting own shares

◆Nexton Bio = Decided to issue convertible bonds worth 10 billion KRW to raise operating funds

◆Novarex = Obtained Indian patent for 'Pharmaceutical composition for prevention or treatment of liver diseases containing glycyrrhizin and liquiritin-containing licorice extract'

◆Abatech = Preliminary Q3 results: sales 20.6 billion KRW, operating loss 0.5 billion KRW

◆U& I = Decided on a 6 billion KRW capital increase to raise operating funds for subsidiary DM Power and to acquire securities of other companies

◆Agabang Company = Preliminary consolidated Q3 results: sales 34.5 billion KRW, operating profit 3.7 billion KRW

◆Studio Santa Claus = Decided to transfer Nexon BioScience shares worth 12.5 billion KRW and issue convertible bonds worth 6 billion KRW to secure cash liquidity for financial structure improvement and new business entry

◆Flitto = Decided to issue convertible bonds worth 10 billion KRW

◆Rix Solution = Decided on a total 20 billion KRW capital increase to raise funds for facilities, operations, and acquisition of securities of other companies

◆CN Plus = Decided to issue convertible bonds worth 1.5 billion KRW to raise operating funds